维普中文期刊产品整合服务
15篇 您的检索式:作者名="Wust Peter"
    题名 作者 年代 出处 被引量
1The cellular and molecular basis of hyperthermia显示文摘Bert Hildebrandt Peter Wust Olaf Ahlers Annette Dieing Geetha Sreenivasa Thoralf Kerner Roland Felix Hanno Riess 2002Critical Reviews in Oncology and Hematology2002,,:3
2Magnetic fluid hyperthermia (MFH) : Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles 显示文摘Andreas Jordan Regina Scholz Peter Wust 1999Journal of Magnetism & Magnetic Materials1999,201,:1
3CT-guided high-dose-rate brachytherapy in the interdisciplinary treatment of patients with liver metastases of pancreatic cancer显示文摘BACKGROUND: CT-guided high-dose-rate brachytherapy(CT-HDRBT) is an interventional radiologic technique for local ablation of primary and secondary malignomas applying a radiation source through a brachycatheter percutaneously into the targeted lesion. The aim of this study was to assess local tumor control, safety and efficacy of CT-HDRBT in the treatment of liver metastases of pancreatic cancer. METHODS: Twenty consecutive patients with 49 unresectable liver metastases of pancreatic cancer were included in this retrospective trial and treated with CT-HDRBT, applied as a single fraction high-dose irradiation(15-20 Gy) using a 192 Irsource. Primary endpoint was local tumor control and secondary endpoints were complications, progression-free survival and overall survival.RESULTS: The mean tumor diameter was 29 mm(range 10-73). The mean irradiation time was 20 minutes(range 7-42). The mean coverage of the clinical target volume was 98%(range 88%-100%). The mean D100 was 18.1 Gy and the median D100 was 19.78 Gy. Three major complications occurred with post-interventional abscesses, three of which were seen in 15 patients with biliodigestive anastomosis(20%)and overall 15%. The mean follow-up time was 13.7 months(range 1.4-55.0). The median progression-free survival was 4.9 months(range 1.4-42.9, mean 9.4). Local recurrence occurred in 5(10%) of 49 metastases treated. The median overall survival after CT-HDRBT was 8.6 months(range 1.5-55.3). Eleven patients received chemotherapy after ablation with a median progression-free survival of 4.9 months(mean 12.9). Nine patients did not receive chemotherapy after intervention with a median progression-free survival of 3.2 months(mean 5.0). The rate of local tumor control was 91% in both groups after 12 months.CONCLUSION: CT-HDRBT was safe and effective for the treatment of liver metastases of pancreatic cancer.Gero Wieners Alexander Christian Schippers Federico Collettini Dirk Schnapauff Bernd Hamm Peter Wust Hanno Riess Bernhard Gebauer 2015Hepatobiliary & Pancreatic Diseases International2015,14,5:1
4Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology显示文摘Holger Amthauer Timm Denecke Beate Rau Bert Hildebrandt Michael Hünerbein Juri Ruf Ulrike Schneider Matthias Gutberlet Peter M. Schlag Roland Felix Peter Wust 2004European Journal of Nuclear Medicine and Molecular Imaging2004,,6:1
5Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology显示文摘Holger Amthauer Timm Denecke Beate Rau Bert Hildebrandt Michael Hünerbein Juri Ruf Ulrike Schneider Matthias Gutberlet Peter M. Schlag Roland Felix Peter Wust 2004European Journal of Nuclear Medicine and Molecular Imaging2004,,:1
6Stress induced changes in lymphocyte subpopulations and associated cytokines during whole body hyperthermia of 41.8–42.2°C显示文摘Olaf Ahlers Bert Hildebrandt Annette Dieing Maria Deja Thomas B?hnke Peter Wust Hanno Riess Herwig Gerlach Thoralf Kerner 2005European Journal of Applied Physiology2005,,4:1
7Stress induced changes in lymphocyte subpopulations and associated cytokines during whole body hyperthermia of 41.8–42.2°C显示文摘Olaf Ahlers Bert Hildebrandt Annette Dieing Maria Deja Thomas B?hnke Peter Wust Hanno Riess Herwig Gerlach Thoralf Kerner 2005European Journal of Applied Physiology2005,,4:1
8Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles 显示文摘Andreas Jordan Regina Scholz Peter Wust 1999Journal of Magnetism & Magnetic Materials1999,201,:1
9Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles 显示文摘Jordan Andreas Scholz Regina Wust Peter 1999Journal of Magnetism and Magnetic Materials1999,,201:1
10The cellular and molecular basis of hyperthermia显示文摘Bert Hildebrant Peter Wust Olaf Ahlers 2002Critical Reviews in Oneolo- gy/Hematology2002,,43:1
11Thermal monitoring: Invasive, minimal-invasive and non-invasive approaches显示文摘Peter Wust Chie Hee Cho Bert Hildebrandt Johanna Gellermann 2006International Journal of Hyperthermia2006,,:1
12The cellular and molecular basis of hyperthermia显示文摘Bert Hildebrandt Peter Wust Olaf Ahlers Annette Dieing Geetha Sreenivasa Thoralf Kerner Roland Felix Hanno Riess 2002Critical Reviews in Oncology and Hematology2002,,1:1
13Computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of metastases adjacent to the liver hilum显示文摘Federico Collettini Anju Singh Dirk Schnapauff Maciej Janusz Powerski Timm Denecke Peter Wust Bernd Hamm Bernhard Gebauer 2013European Journal of Radiology2013,,:1
14Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles显示文摘Jordan Andreas Scholz Regina Wust Peter 1999Journal of Magnetism and Magnetic Materials1999,,201:1
15The cellular and molecular basis of hyperthermia 显示文摘Hildebrandt Bert Wust Peter Ahlers Olaf 2002Critical Reviews in Oncolo- gy/Hematology2002,43,1:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费